Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Eur Rev Med Pharmacol Sci ; 27(4 Suppl): 1-5, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-37350686

RESUMO

OBJECTIVE: The study aims to define butterbur's impact on nasal cells' viability and proliferation. After topically administering butterbur to the nasal epithelial cells, research has been done to see if butterbur has any harmful effect on the nasal cells. MATERIALS AND METHODS: Specimens of healthy primary nasal epithelium were collected from the subjects and incubated in cell culture in due course of septoplasty. After implementing 2.5 µM butterbur in cultured cells, cell viability was defined via trypan blue assay, and proliferation was defined via the XTT method. The number of total cells, viability, and proliferation was defined. XTT (2, 3-bis-(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide) experiments can be used to evaluate cellular toxicity. RESULTS: The findings of the XTT experiment reveal no harm to nasal cells after topical implementation of butterbur. No significant change in the proliferation of the cells, no matter what the doses are. There was no cytotoxic effect on the primary nasal cells at the end of 24 hours of implementation, and no side effects were found. There was no difference in cells' viability between the experimental group with butterbur application and the control group. CONCLUSIONS: Cytotoxicity on nasal cells was not observed after the butterbur application. Even if there have been some indications of liver toxicity, butterbur can be suggested as a safe option for seasonal allergic rhinitis. Further studies related to the toxicity of topical butterbur are also recommended, even though this study indicates no cytotoxicity from the topical application on nasal cells.


Assuntos
Petasites , Rinite Alérgica Sazonal , Humanos , Mucosa Nasal , Células Epiteliais
2.
Eur Rev Med Pharmacol Sci ; 27(4 Suppl): 76-82, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-37350692

RESUMO

OBJECTIVE: We investigated the effects of tannic acid on viability and proliferation of nasal cells after topical application. It was also evaluated whether tannic acid served as an alternative treatment agent. MATERIALS AND METHODS: Collected primary nasal epithelium from healthy people who had undergone septoplasty operations were incubated in cell culture. Following the implementation of 2.5 µM tannic acid in cultured cells, both the number of total cells and their viability were measured using the trypan blue assay, while proliferation was assessed through the XTT method. The XTT method, which involves using "2,3-bis-(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide", is a reliable means of determining cellular toxicity. RESULTS: XTT experiment results showed that there was no harm was detected to nasal cells after tannic acid's topical implementation. There were no significant changes in cell proliferation; moreover, no matter what the doses were. Additionally, no cytotoxic effects were detected on nasal cells' primary culture at "the end of the 24 hours of implementation". There was no side effect of it, either. CONCLUSIONS: According to the research, the application of tannic acid topically did not result in any harmful effects on the nasal cell culture. Tannic acid's potential anti-inflammatory properties and its ability to decrease Th2-related cytokines suggest that it may be beneficial for patients with rhinosinusitis or allergic rhinitis, pending confirmation through clinical trials. Additionally, if clinical trials confirm its effectiveness, tannic acid may be useful in healing wounds for patients undergoing septorhinoplasty.


Assuntos
Antineoplásicos , Sinusite , Humanos , Taninos/farmacologia , Sinusite/tratamento farmacológico , Antineoplásicos/uso terapêutico , Anti-Inflamatórios/uso terapêutico
3.
Eur Rev Med Pharmacol Sci ; 27(2 Suppl): 39-43, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36971219

RESUMO

OBJECTIVE: This study aimed to define the impacts of curcumin on nasal cell viability and proliferation. MATERIALS AND METHODS: Specimens of healthy primary nasal epithelium were collected and incubated in cell culture during septorhinoplasty from people who signed a consent form. After implementing 2.5 µM curcumin in cultured cells, cell viability was defined via trypan blue assay, and proliferation was defined via the XTT method. The number of total cells, viability, and proliferation was defined. XTT (2,3-bis-(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-5-carboxanilide) experiments can be used to evaluate cellular toxicity. RESULTS: The results revealed no harm to nasal cells after the topical implementation of curcumin. There was no significant change in the proliferation of the cells related to 24 hours of implementation. There was no adverse effect of using curcumin on the cell viability, either. CONCLUSIONS: No cytotoxic effect on nasal cells has been observed after applying topically implemented curcumin. Curcumin could be used topically for an alternative treatment for allergic rhinitis as it has anti-inflammatory and immune response modulatory effects if clinical trials will confirm experimental data.


Assuntos
Antineoplásicos , Curcumina , Rinite Alérgica , Humanos , Curcumina/farmacologia , Mucosa Nasal
4.
Bratisl Lek Listy ; 121(2): 111-116, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32115962

RESUMO

AIM: We aimed to determine the possible correlation between voltage­gated potassium channels and micro RNAs in breast cancer and metastatic breast cancer cells. METHOD: Kv1.3 and Kv10.1 channels were inhibited by specific siRNAs using a lipofectamine-based transfection in MCF-7 and MDA-MB-231 cells. After transfection, total RNA was isolated, and then miR-126 and miR-126* expressions were observed using RT-PCR. RESULTS: There was a negative correlation between Kv channels and miRNAs according to the characteristics of the breast cancer cells. The inhibition was observed not only in Kv1.3 but also in Kv10.1 in MCF-7 cells, and miR-126 and miR-126* expressions were downregulated compared to the control group (p < 0.001). The inhibition of these channels in MDA-MB-231 cells caused an upregulation of miR-126 and miR-126* expressions (p < 0.001). CONCLUSION: The miR-126 and miR-126* expressions differed according to benign and malign breast cancer cell lines. Furthermore, we found that miR-126/126* may interact with Kv1.3 and Kv10.1 voltage-gated potassium channels. Our study suggests and indicates the relationship between Kv channels and miRNAs in breast cancer cells (Tab. 1, Fig. 2, Ref. 51).


Assuntos
Neoplasias da Mama , Regulação Neoplásica da Expressão Gênica , MicroRNAs , Canais de Potássio de Abertura Dependente da Tensão da Membrana , Neoplasias da Mama/metabolismo , Linhagem Celular Tumoral , Humanos , Células MCF-7 , MicroRNAs/metabolismo
5.
Bratisl Lek Listy ; 117(11): 639-647, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-28125889

RESUMO

BACKGROUND: Micro RNA-126 is known to enhance apoptotic processes and also plays a role in vascular growth through the regulation of vascular endothelial growth factor-mediated signaling, angiogenesis, and vascular integrity. OBJECTIVES: We aimed to determine the role of miR-126 in breast cancer cell lines with a variety of different characteristics to evaluate its interaction with certain cancer-related molecules and mechanisms. METHODS: To determine the effect of presence and absence of miR-126 in MCF-7 and MDA-MB-231 breast cancer cells, miR-126 mimics and inhibitor were transfected. miRNA and gene expressions were observed by using RT-PCR. Viability, proliferation, adhesion, invasion and lateral motility assays were performed to determine cell behavior changes. RESULTS: miR-126 is more effective on MDA-MB-231 cells on cell behavior. We observed an increase in miR-126 expression when miR-126 mimics was transfected to MCF-7 and MDA-MB-231 cells. Also, there was a decrease in miR-126 expression when MCF-7 and MDA-MB-231 cells were transfected with miR-126 inhibitor. Furthermore, presence and absence of miR-126 modulated the gene expressions of VEGF/PI3K/AKT and MAPK signaling in MCF-7 and MDA-MB-231. CONCLUSION: Our study showed that miR-126 is in a state of interaction with a multitude molecules playing a role in breast cancer. According to obtained data, we can say that miR-126 may be more effective in inhibition of metastatic breast cancer (Tab. 4, Fig. 3, Ref. 46).


Assuntos
Apoptose , Neoplasias da Mama/patologia , Movimento Celular/genética , MicroRNAs/genética , Fosfatidilinositol 3-Quinases/metabolismo , Fator A de Crescimento do Endotélio Vascular/genética , Neoplasias da Mama/genética , Linhagem Celular Tumoral , Proliferação de Células , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Células MCF-7 , MicroRNAs/metabolismo , Metástase Neoplásica , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Transdução de Sinais , Fatores de Transcrição/genética , Fatores de Transcrição/metabolismo , Transfecção
6.
Eur Rev Med Pharmacol Sci ; 18(1): 10-27, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24452937

RESUMO

OBJECTIVE: Studies in animals have provided key evidence that antagonizing TNF-α is a viable therapeutic strategy for diffuse severe brain injury. This study is planned to prevent post-traumatic secondary tissue damages in rat diffuse severe brain injury model, which is induced by alone or combined administration of Etanercept and lithium chloride (LiCl). MATERIALS AND METHODS: Male Sprague-Dawley rats were used in the current study. Rats were divided into 5 groups. Trauma was not induced and treatment was not applied to rats of Sham group. For rats of Trauma+Saline group, saline 0.9% was administered via intraperitoneal (i.p.) route at dose of 1 mg/100 g body weight 1 hour after trauma. For rats of Trauma+Etanercept group, Etanercept was administered via i.p. route at dose of 5 mg/kg body weight 1 hour after trauma. For rats of Trauma+LiCl group, LiCl was administered via i.p. route at dose of 50 mg/kg body weight 1 hour after trauma. For rats of Etanercept+LiCl group, Etanercept and LiCl were administered via i.p. route at dose of 5 mg/kg body weight and 50 mg/kg body weight, respectively, 1 hour after trauma. Serum glial fibrillary acidic protein (GFAP) and Tau levels were analyzed with ELISA. For analyses H&E, TUNEL, GFAP and TNF-α staining methods were used. RESULTS: We demonstrate that Etanercept treatment reduced the TBI-induced brain tissues alteration, reduced the expression of TNF-α and improve edema and axonal swelling. We observed a significant decrease in TNF-α and GFAP positivity after LiCl was administered. CONCLUSIONS: The findings obtained in this study suggest that the combination therapy with Etanercept and LiCl decreased neuronal degeneration and alleviated secondary tissue damage in post-traumatic period.


Assuntos
Lesões Encefálicas/tratamento farmacológico , Imunoglobulina G/uso terapêutico , Cloreto de Lítio/uso terapêutico , Fármacos Neuroprotetores/uso terapêutico , Receptores do Fator de Necrose Tumoral/uso terapêutico , Animais , Apoptose/efeitos dos fármacos , Astrócitos/efeitos dos fármacos , Astrócitos/metabolismo , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Encéfalo/patologia , Lesões Encefálicas/metabolismo , Lesões Encefálicas/patologia , Modelos Animais de Doenças , Quimioterapia Combinada , Etanercepte , Proteína Glial Fibrilar Ácida/sangue , Proteína Glial Fibrilar Ácida/metabolismo , Imunoglobulina G/farmacologia , Cloreto de Lítio/farmacologia , Masculino , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Neurônios/patologia , Fármacos Neuroprotetores/farmacologia , Ratos Sprague-Dawley , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fator de Necrose Tumoral alfa/metabolismo , Proteínas tau/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA